What The Study Did: In this randomized clinical trial, a physician messaging campaign was effective in increasing COVID-19 knowledge, information-seeking and self-reported protective behaviors among diverse groups.
More doesn't necessarily mean better - including in cancer treatment. University of Pittsburgh School of Medicine and University of Wisconsin-Madison scientists report today in Science Translational Medicine that combining targeted radiopharmaceutical therapy with immunotherapy significantly boosts eradication of metastatic cancer in mice, even when the radiation is given in doses too low to destroy the cancer outright.
An international grassroots-funded multicenter clinical trial found that giving a full dose of heparin early to moderately ill hospitalized COVID-19 patients reduced the odds of all-cause death by 78 percent.
Males with COVID-19 had significantly higher rates of hospitalization and of transfer to the intensive care unit (ICU) according to a new study. A higher percentage of males died of COVID-19 compared to females
Aerin Medical Inc. today announced that the International Forum of Allergy and Rhinology has published three-month results online from the VATRAC trial, confirming the safety and efficacy of VivAer® for the treatment of nasal airway obstruction (NAO) caused by nasal valve collapse (NVC). In the study, those treated with VivAer showed significant improvement in nasal obstruction symptoms compared to the control group.
Patients with Achilles tendinopathy, a disease of the Achilles tendon that can potentially cause significant pain, receive no benefit from being treated with platelet rich plasma (PRP) injection, a clinical trial led by the University of Warwick has found.
A world-first trial has shown that nose drops of modified 'friendly' bacteria protect against meningitis.
Using an existing drug for late-stage kidney cancer at an earlier stage of the disease could reduce the risk of cancer recurring by a third, according to new research.
Obese patients with a form of advanced prostate cancer survive longer than overweight and normal weight patients, new research has found.
A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumour cells, is well tolerated by patients and keeps them alive for longer than standard care, found a phase 3 trial to be presented at the European Association of Urology congress, EAU21, today.